SK Bioscience joins US-backed project to develop Bundibugyo Ebola vaccine
Source ↗
👁 0
💬 0
SK Bioscience will join global partners in a U.S. government-funded project to develop and produce a vaccine against the Bundibugyo virus, a strain of Ebola spreading in the Democratic Republic of the Congo, the Korean vaccine maker said Thursday. The project, carried out with the International AIDS Vaccine Initiative (IAVI), a global nonprofit biomedical research organization, and Singapore-based Hilleman Laboratories, will receive up to 130.9 billion won ($99 million) from the Biomedical Advan
Comments (0)